Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab

Bin Xiao; Eng-King Tan

doi:10.1002/ctm2.1559

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1559 DOI: 10.1002/ctm2.1559

COMMENTARY

Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab

Bin Xiao ¹^,²^,^†
, Eng-King Tan ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Bin Xiao,Eng-King Tan. Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab. Clinical and Translational Medicine, 2024, 14(1): e1559 DOI:10.1002/ctm2.1559

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.